
Global Oral Vaccine for Human Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Oral Vaccine for Human market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Oral Vaccine for Human market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Oral Vaccine for Human market include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Oral Vaccine for Human, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Oral Vaccine for Human, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Vaccine for Human, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oral Vaccine for Human sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oral Vaccine for Human market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Oral Vaccine for Human sales, projected growth trends, production technology, application and end-user industry.
Oral Vaccine for Human Segment by Company
Bibcol
Bio-Med
EuBiologics
Halfkin Bio-Pharmaceuticals
Panacea Biotec Ltd
PaxVax
Serum Institute
Vabiotech
Valneva
Tiantan Biological
GSK
Merck
Sanofi
Shanghai United Cell
Lanzhou Institute
Oral Vaccine for Human Segment by Type
Cholera Vaccine
Oral Polio Vaccine
Rotavirus Vaccine
Other
Oral Vaccine for Human Segment by Application
Public
Private
Oral Vaccine for Human Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Oral Vaccine for Human status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Oral Vaccine for Human market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oral Vaccine for Human significant trends, drivers, influence factors in global and regions.
6. To analyze Oral Vaccine for Human competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Oral Vaccine for Human market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Vaccine for Human industry.
Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Oral Vaccine for Human in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Oral Vaccine for Human market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Oral Vaccine for Human market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Oral Vaccine for Human is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Oral Vaccine for Human market include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Oral Vaccine for Human, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Oral Vaccine for Human, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Vaccine for Human, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oral Vaccine for Human sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oral Vaccine for Human market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Oral Vaccine for Human sales, projected growth trends, production technology, application and end-user industry.
Oral Vaccine for Human Segment by Company
Bibcol
Bio-Med
EuBiologics
Halfkin Bio-Pharmaceuticals
Panacea Biotec Ltd
PaxVax
Serum Institute
Vabiotech
Valneva
Tiantan Biological
GSK
Merck
Sanofi
Shanghai United Cell
Lanzhou Institute
Oral Vaccine for Human Segment by Type
Cholera Vaccine
Oral Polio Vaccine
Rotavirus Vaccine
Other
Oral Vaccine for Human Segment by Application
Public
Private
Oral Vaccine for Human Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Oral Vaccine for Human status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Oral Vaccine for Human market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oral Vaccine for Human significant trends, drivers, influence factors in global and regions.
6. To analyze Oral Vaccine for Human competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Oral Vaccine for Human market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Vaccine for Human industry.
Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Oral Vaccine for Human in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
193 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Oral Vaccine for Human Sales Value (2020-2031)
- 1.2.2 Global Oral Vaccine for Human Sales Volume (2020-2031)
- 1.2.3 Global Oral Vaccine for Human Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Oral Vaccine for Human Market Dynamics
- 2.1 Oral Vaccine for Human Industry Trends
- 2.2 Oral Vaccine for Human Industry Drivers
- 2.3 Oral Vaccine for Human Industry Opportunities and Challenges
- 2.4 Oral Vaccine for Human Industry Restraints
- 3 Oral Vaccine for Human Market by Company
- 3.1 Global Oral Vaccine for Human Company Revenue Ranking in 2024
- 3.2 Global Oral Vaccine for Human Revenue by Company (2020-2025)
- 3.3 Global Oral Vaccine for Human Sales Volume by Company (2020-2025)
- 3.4 Global Oral Vaccine for Human Average Price by Company (2020-2025)
- 3.5 Global Oral Vaccine for Human Company Ranking (2023-2025)
- 3.6 Global Oral Vaccine for Human Company Manufacturing Base and Headquarters
- 3.7 Global Oral Vaccine for Human Company Product Type and Application
- 3.8 Global Oral Vaccine for Human Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Oral Vaccine for Human Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Oral Vaccine for Human Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Oral Vaccine for Human Market by Type
- 4.1 Oral Vaccine for Human Type Introduction
- 4.1.1 Cholera Vaccine
- 4.1.2 Oral Polio Vaccine
- 4.1.3 Rotavirus Vaccine
- 4.1.4 Other
- 4.2 Global Oral Vaccine for Human Sales Volume by Type
- 4.2.1 Global Oral Vaccine for Human Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Oral Vaccine for Human Sales Volume by Type (2020-2031)
- 4.2.3 Global Oral Vaccine for Human Sales Volume Share by Type (2020-2031)
- 4.3 Global Oral Vaccine for Human Sales Value by Type
- 4.3.1 Global Oral Vaccine for Human Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Oral Vaccine for Human Sales Value by Type (2020-2031)
- 4.3.3 Global Oral Vaccine for Human Sales Value Share by Type (2020-2031)
- 5 Oral Vaccine for Human Market by Application
- 5.1 Oral Vaccine for Human Application Introduction
- 5.1.1 Public
- 5.1.2 Private
- 5.2 Global Oral Vaccine for Human Sales Volume by Application
- 5.2.1 Global Oral Vaccine for Human Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Oral Vaccine for Human Sales Volume by Application (2020-2031)
- 5.2.3 Global Oral Vaccine for Human Sales Volume Share by Application (2020-2031)
- 5.3 Global Oral Vaccine for Human Sales Value by Application
- 5.3.1 Global Oral Vaccine for Human Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Oral Vaccine for Human Sales Value by Application (2020-2031)
- 5.3.3 Global Oral Vaccine for Human Sales Value Share by Application (2020-2031)
- 6 Oral Vaccine for Human Regional Sales and Value Analysis
- 6.1 Global Oral Vaccine for Human Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Oral Vaccine for Human Sales by Region (2020-2031)
- 6.2.1 Global Oral Vaccine for Human Sales by Region: 2020-2025
- 6.2.2 Global Oral Vaccine for Human Sales by Region (2026-2031)
- 6.3 Global Oral Vaccine for Human Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Oral Vaccine for Human Sales Value by Region (2020-2031)
- 6.4.1 Global Oral Vaccine for Human Sales Value by Region: 2020-2025
- 6.4.2 Global Oral Vaccine for Human Sales Value by Region (2026-2031)
- 6.5 Global Oral Vaccine for Human Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Oral Vaccine for Human Sales Value (2020-2031)
- 6.6.2 North America Oral Vaccine for Human Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Oral Vaccine for Human Sales Value (2020-2031)
- 6.7.2 Europe Oral Vaccine for Human Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Oral Vaccine for Human Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Oral Vaccine for Human Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Oral Vaccine for Human Sales Value (2020-2031)
- 6.9.2 South America Oral Vaccine for Human Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Oral Vaccine for Human Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Oral Vaccine for Human Sales Value Share by Country, 2024 VS 2031
- 7 Oral Vaccine for Human Country-level Sales and Value Analysis
- 7.1 Global Oral Vaccine for Human Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Oral Vaccine for Human Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Oral Vaccine for Human Sales by Country (2020-2031)
- 7.3.1 Global Oral Vaccine for Human Sales by Country (2020-2025)
- 7.3.2 Global Oral Vaccine for Human Sales by Country (2026-2031)
- 7.4 Global Oral Vaccine for Human Sales Value by Country (2020-2031)
- 7.4.1 Global Oral Vaccine for Human Sales Value by Country (2020-2025)
- 7.4.2 Global Oral Vaccine for Human Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.9.2 France Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.16.2 China Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.19.2 India Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Oral Vaccine for Human Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Oral Vaccine for Human Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Oral Vaccine for Human Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Bibcol
- 8.1.1 Bibcol Comapny Information
- 8.1.2 Bibcol Business Overview
- 8.1.3 Bibcol Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Bibcol Oral Vaccine for Human Product Portfolio
- 8.1.5 Bibcol Recent Developments
- 8.2 Bio-Med
- 8.2.1 Bio-Med Comapny Information
- 8.2.2 Bio-Med Business Overview
- 8.2.3 Bio-Med Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
- 8.2.5 Bio-Med Recent Developments
- 8.3 EuBiologics
- 8.3.1 EuBiologics Comapny Information
- 8.3.2 EuBiologics Business Overview
- 8.3.3 EuBiologics Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
- 8.3.5 EuBiologics Recent Developments
- 8.4 Halfkin Bio-Pharmaceuticals
- 8.4.1 Halfkin Bio-Pharmaceuticals Comapny Information
- 8.4.2 Halfkin Bio-Pharmaceuticals Business Overview
- 8.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
- 8.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
- 8.5 Panacea Biotec Ltd
- 8.5.1 Panacea Biotec Ltd Comapny Information
- 8.5.2 Panacea Biotec Ltd Business Overview
- 8.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
- 8.5.5 Panacea Biotec Ltd Recent Developments
- 8.6 PaxVax
- 8.6.1 PaxVax Comapny Information
- 8.6.2 PaxVax Business Overview
- 8.6.3 PaxVax Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.6.4 PaxVax Oral Vaccine for Human Product Portfolio
- 8.6.5 PaxVax Recent Developments
- 8.7 Serum Institute
- 8.7.1 Serum Institute Comapny Information
- 8.7.2 Serum Institute Business Overview
- 8.7.3 Serum Institute Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
- 8.7.5 Serum Institute Recent Developments
- 8.8 Vabiotech
- 8.8.1 Vabiotech Comapny Information
- 8.8.2 Vabiotech Business Overview
- 8.8.3 Vabiotech Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
- 8.8.5 Vabiotech Recent Developments
- 8.9 Valneva
- 8.9.1 Valneva Comapny Information
- 8.9.2 Valneva Business Overview
- 8.9.3 Valneva Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Valneva Oral Vaccine for Human Product Portfolio
- 8.9.5 Valneva Recent Developments
- 8.10 Tiantan Biological
- 8.10.1 Tiantan Biological Comapny Information
- 8.10.2 Tiantan Biological Business Overview
- 8.10.3 Tiantan Biological Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
- 8.10.5 Tiantan Biological Recent Developments
- 8.11 GSK
- 8.11.1 GSK Comapny Information
- 8.11.2 GSK Business Overview
- 8.11.3 GSK Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.11.4 GSK Oral Vaccine for Human Product Portfolio
- 8.11.5 GSK Recent Developments
- 8.12 Merck
- 8.12.1 Merck Comapny Information
- 8.12.2 Merck Business Overview
- 8.12.3 Merck Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Merck Oral Vaccine for Human Product Portfolio
- 8.12.5 Merck Recent Developments
- 8.13 Sanofi
- 8.13.1 Sanofi Comapny Information
- 8.13.2 Sanofi Business Overview
- 8.13.3 Sanofi Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Sanofi Oral Vaccine for Human Product Portfolio
- 8.13.5 Sanofi Recent Developments
- 8.14 Shanghai United Cell
- 8.14.1 Shanghai United Cell Comapny Information
- 8.14.2 Shanghai United Cell Business Overview
- 8.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
- 8.14.5 Shanghai United Cell Recent Developments
- 8.15 Lanzhou Institute
- 8.15.1 Lanzhou Institute Comapny Information
- 8.15.2 Lanzhou Institute Business Overview
- 8.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
- 8.15.5 Lanzhou Institute Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Oral Vaccine for Human Value Chain Analysis
- 9.1.1 Oral Vaccine for Human Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Oral Vaccine for Human Sales Mode & Process
- 9.2 Oral Vaccine for Human Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Oral Vaccine for Human Distributors
- 9.2.3 Oral Vaccine for Human Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.